Latest period
$13.9M
YoY change
-50.4%
5Y CAGR
-6.4%
Peak year (FY2022)
$44.2M
Latest annual
$15M
Stock-Based Compensation history chart for Relmada Therapeutics (RLMD) from 2017 to 2025
Latest: $15M
Stock-Based Compensation growth chart for Relmada Therapeutics (RLMD) from 2017 to 2025
Latest: -50.4%
Stock-Based Compensation history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| FY2025 | $15M | -50.4% | -$15.2M | ||
| FY2024 | $30.2M | -31.1% | -$13.6M | ||
| FY2023 | $43.8M | -0.9% | -$384K | ||
| FY2022 | $44.2M | +9.1% | +$3.7M | ||
| FY2021 | $40.5M | +94.9% | +$19.7M | ||
| FY2020 | $20.8M | +752427.1% | +$20.8M | ||
| FY2019 | $2.76K | -99.8% | -$1.21M | ||
| FY2018 | $1.21M | +134.4% | +$696K | ||
| FY2017 | $518K | -26.5% | -$186K | ||
| FY2016 | $704K | -41.6% | -$503K | ||
| FY2015 | $1.21M | +51.5% | +$410K | ||
| FY2014 | $797K | +5405.0% | +$782K | ||
| FY2013 | $14.5K | — | +$14.5K | ||
| FY2012 | $0.00 | — | — |
- FY2025$15M-50.4%
- FY2024$30.2M-31.1%
- FY2023$43.8M-0.9%
- FY2022$44.2M+9.1%
- FY2021$40.5M+94.9%
- FY2020$20.8M+752427.1%
- FY2019$2.76K-99.8%
- FY2018$1.21M+134.4%
- FY2017$518K-26.5%
- FY2016$704K-41.6%
- FY2015$1.21M+51.5%
- FY2014$797K+5405.0%
- FY2013$14.5K—
- FY2012$0.00—
Stock-Based Compensation values are taken from Relmada Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Relmada Therapeutics (RLMD)
Stock-Based Compensation for Relmada Therapeutics (RLMD): headline value $13.9M · YoY -50.4%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Relmada Therapeutics (RLMD) stock-based compensation totalled $15M – plunged 50.4% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Relmada Therapeutics stock-based compensation compounded at -6.4% per year, with a net decline across the window.
The record annual stock-based compensation stands at $44.2M, reached in 2022; the historical low of $0.00 was recorded in 2012.
Relmada Therapeutics Stock-Based Compensation by Year
Relmada Therapeutics Stock-Based Compensation 2025: $15M
In 2025, Relmada Therapeutics reported stock-based compensation of $15M, plunged 50.4% below 2024.
Relmada Therapeutics Stock-Based Compensation 2024: $30.2M
Relmada Therapeutics stock-based compensation in 2024 was $30.2M, plunged 31.1% below 2023.
Relmada Therapeutics Stock-Based Compensation 2023: $43.8M
2023's stock-based compensation for Relmada Therapeutics came in at $43.8M, edged down 0.9% below 2022.
Relmada Therapeutics Stock-Based Compensation 2022: $44.2M
Relmada Therapeutics posted stock-based compensation of $44.2M in 2022, grew 9.1% from 2021. This figure represents the highest annual value in the available history.
Relmada Therapeutics Stock-Based Compensation 2021: $40.5M
Relmada Therapeutics stock-based compensation in 2021 was $40.5M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Stock-Based Compensation
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest stock-based compensation
| $1.35B | |
| $971M | |
| $955M | |
| $626M | |
| $494M | |
| $310M | |
| $0.00 | |
| $0.00 |
- $1.35B
- $955M
- $626M
- $494M
- $0.00
- $0.00
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.